Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim Retreatment in Crohn's Disease
NCT00206713Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jul 2004
- Primary completion
- Oct 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Sargramostim with Placebo (2 arms). Primary endpoint: Proportion of patients achieving clinical response or remission at Day 57. Started Jul 2004; status: terminated.
02
Drugs
sargramostim
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00206713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206713.